Topics

Idiopathic Pulmonary Fibrosis Market Review, Epidemiology And Market Forecast 2029 [Published by First View Insight] Prices from USD $2975

00:06 EDT 27 Mar 2020 | BioPortfolio Reports

FirstView Market Insight Idiopathic Pulmonary Fibrosis Market Review, Epidemiology And Market Forecast 2029 provides in depth understanding of historical and forecasted epidemiology along with the detailed market insights.The report covers detailed information on the disease, treatment algorithm, existing treatment and upcoming treatment regimens, unmet needs, market drivers, market barriers, sales trend and market revenue during study period 20182029.IPF is a form of progressive pulmonary fibrosis, or abnormal scarring of the lungs. As the scarring progresses, transfer of oxygen into the bloodstream is increasingly impaired, leading to irreversible loss of lung function as well as high morbidity and mortality rates. Average life expectancy is estimated to be three to five years from diagnosis, with approximately twothirds of patients dying within five years of diagnosis. Survival rates are comparable to those for some of the deadliest cancers.Overview

This report contains comprehensive overview of disease including disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends, as well as details about treatment algorithms and treatment guidelines

Epidemiology Forecast

This section encompasses information on the incidence and prevalence of disease in EU5, US Japan. It also provides historical, current and forecasted estimates of diagnosed/treatable patient population.

Existing and upcoming treatment landscape

Captures the evolution of treatment paradigm including the current and emerging drug therapies. Provides information on the clinical trial results, mechanism of action, route of administration, therapeutic positioning, regulatory milestones and patent exclusivity. It gives insight into the potential therapeutic targets for drug development. The section also covers major events and latest happenings, deals and collaborations.

Market Size

This section of report will address the major issues, on the size and total addressable market share. This will help the companies to understand and visualize their business prospects and make major decisions based on the historical, current and forecasted market share across the globe. Analyze the commercial potential of the product as well as the disease/therapy area.


Market Trends Unmet needs

This section of the report helps to understand the market trend and opportunities by analyzing the impact of current therapies on the market, current and future unmet needs, drivers and barriers and demand of better technology. This is determined by analyzing the impact of various factors such as mechanism of action, route, cost of therapy, patient segmentation, existing available treatments, compliance and need of the market, expected launch timelines, competitors, brand value and KOLs perception.


List of products

Esbriet MAPK Inhibitor

Ofev Tyrosine Kinase Inhibitor

GLPG 1690 Autotaxin Inhibitors

Original Article: Idiopathic Pulmonary Fibrosis Market Review, Epidemiology And Market Forecast 2029 [Published by First View Insight] Prices from USD $2975

NEXT ARTICLE

More From BioPortfolio on "Idiopathic Pulmonary Fibrosis Market Review, Epidemiology And Market Forecast 2029 [Published by First View Insight] Prices from USD $2975"

Quick Search

Relevant Topics

Pulmonary
Pulmonary relating to or associated with the lungs eg Asthma, chronic bronchitis, emphysema, COPD, Cystic Fibrosis, Influenza,  Lung Cancer, Pneumonia, Pulmonary Arterial Hypertension, Sleep Disorders etc Follow and track Lung Cancer News ...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...